Summary & Overview
CPT 83663: Fetal Lung Maturity Test, Fluorescence Polarization
CPT code 83663 represents a fluorescence polarization laboratory test used to assess fetal lung maturity, a clinical measure that helps determine whether a fetus’s pulmonary system is likely to sustain life outside the uterus. Nationally, this test is relevant for prenatal care management, delivery planning in high-risk pregnancies, and decisions about timing of steroid administration or delivery when fetal maturity is uncertain.
Major national payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines typical coverage considerations and benchmarking practice patterns across these payers. It highlights how payer policies can influence utilization of fetal lung maturity testing in late-preterm and early-term scenarios.
Readers will find a concise clinical context for the assay, an overview of common billing modifiers and service delivery settings, and a summary of what benchmarks and policy updates are typically reviewed for such laboratory procedures. The report focuses on national implications for care coordination, laboratory service planning, and payer reimbursement frameworks. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 83663 describes a laboratory fluorescence polarization test performed by a lab analyst to assess fetal lung maturity. The assay evaluates biochemical markers in fetal samples to indicate whether the fetal pulmonary system is likely to support life outside the uterus.
-
Service type: Laboratory diagnostic test assessing fetal lung maturity
-
Typical site of service: Clinical laboratory or hospital laboratory performing specialized prenatal testing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A maternal-fetal medicine laboratory receives a maternal blood specimen from a pregnant patient at 32–38 weeks gestation for assessment of fetal lung maturity using a fluorescence polarization test (83663). Typical indication is when delivery timing may be uncertain and clinicians need objective information about surfactant production to guide decisions about planned early delivery or expectant management. A common scenario: a patient with preterm premature rupture of membranes at 35 weeks and maternal comorbidity (for example, preeclampsia) has a stat order from the obstetrician; the specimen is transported to the lab, accessioned, and the lab analyst performs the fluorescence polarization assay. Results are reported to the ordering provider and placed in the maternal chart to inform neonatal respiratory risk counseling.
-
Service Type: Laboratory diagnostic test — fetal lung maturity assay.
-
Typical Site of Service: Hospital laboratory, clinical reference laboratory, or maternal-fetal medicine service within an acute-care facility.
-
Typical Patient Scenario: Pregnant patient at risk for preterm delivery (eg, preeclampsia, premature rupture of membranes, placental abruption, or need for indicated preterm cesarean) where determination of fetal surfactant maturity will influence timing of delivery or neonatal preparedness. The test is ordered as a single procedure, often with STAT priority when delivery is imminent.
-
Workflow Summary: Specimen collection (maternal blood or amniotic fluid per institutional protocol) → specimen labeling and transport → lab accession and priority processing → fluorescence polarization assay performed by lab analyst (
83663) → result validated and released to ordering provider and electronic medical record → clinical decision-making regarding delivery timing and neonatal respiratory support.